Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fusion Clear all
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

NCT01454739
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIIIFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
0 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MEK162 for Children With Low-Grade Gliomas

NCT02285439
View directory record Official record
Conditions
Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions
MEK162
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 2, 2026, 10:04 PM EDT
Completed No phase listed Observational

Osteocel® Plus in Anterior Lumbar Interbody Fusion (ALIF)

NCT00948831
View directory record Official record
Conditions
Degenerative Disc Disease, Lumbar
Interventions
Osteocel Plus
Biological
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
San Francisco, California • Indianapolis, Indiana • Kokomo, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 2, 2026, 10:04 PM EDT
Active, not recruiting Not applicable Interventional

LimiFlex Clinical Trial for the Treatment of Degenerative Spondylolisthesis With Spinal Stenosis

NCT03115983
View directory record Official record
Conditions
Degenerative Spondylolisthesis, Lumbar Spinal Stenosis
Interventions
LimiFlex, Fusion Instrumentation, Decompression, Fusion
Device · Procedure
Lead sponsor
Empirical Spine, Inc.
Industry
Eligibility
25 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
28
States / cities
Tempe, Arizona • Oakland, California • Redwood City, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 2, 2026, 10:04 PM EDT
Terminated Not applicable Interventional Results available

Dynesys Spinal System Post Market 522 Study

NCT01528072
View directory record Official record
Conditions
Degenerative Spondylolisthesis, Pseudoarthrosis
Interventions
Dynesys Spinal System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
20 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Belleville, Illinois • Baltimore, Maryland • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

NCT04176991
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
CTI-1601, Placebo
Biological
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 2, 2026, 10:04 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prophylactic Racemic Epinephrine in Anterior Cervical Discectomy and Fusion

NCT02724761
View directory record Official record
Conditions
Dysphagia, Dysphonia, Postoperative Pain
Interventions
Racemic Epinephrine, Placebo (for racemic epinephrine)
Drug
Lead sponsor
Andrew Chung
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 2, 2026, 10:04 PM EDT
Recruiting Phase 1 Interventional

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

NCT04429542
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Interventions
BCA101, Pembrolizumab
Drug
Lead sponsor
Bicara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 2, 2026, 10:04 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures

NCT03527966
View directory record Official record
Conditions
Lumbar Spine Degeneration
Interventions
5cc Vivigen and local autograft, Small kit rhBMP-2 with local autograft
Biological
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 2, 2026, 10:04 PM EDT
Enrolling by invitation No phase listed Observational

OsteoFlo HydroFiber Ambispective Evaluation

NCT07784673
View directory record Official record
Conditions
OsteoFlo HydroFiber
Interventions
OsteoFlo HydroFiber
Device
Lead sponsor
SurGenTec LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Naperville, Illinois • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

NCT03205163
View directory record Official record
Conditions
Hemophilia A
Interventions
Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose), BIVV001 (High Dose)
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 2, 2026, 10:04 PM EDT
Not listed Not applicable Interventional

Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device

NCT02524860
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal-Fusion Bx
Device
Lead sponsor
Focal Healthcare Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery

NCT02985762
View directory record Official record
Conditions
Spinal Fusion, Pain Management
Interventions
EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Evaluation of Open-Label Conditioned Placebo Analgesia for Postoperative Opioid Reduction Following Spinal Fusion

NCT04574388
View directory record Official record
Conditions
Spine Surgery
Interventions
open label placebo
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Skeletal Muscle and Adipose Tissue Study

NCT03190668
View directory record Official record
Conditions
Idiopathic Scoliosis
Interventions
Bolus dose of Cefazolin, Continuous Cefazolin drip, Paraspinal muscle microdialysis catheters, Subcutaneous microdialysis catheters
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 20 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion

NCT02424591
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Repeat Courses of IM Alefacept

NCT00233662
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Irvine, California • San Francisco, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Safety Study of Preservon-Treated Bone Implants for Cervical Fusion in the Treatment of Cervical Radiculopathy or Myelopathy

NCT00344890
View directory record Official record
Conditions
Cervical Radiculopathy, Myelopathy
Interventions
Anterior Cervical Discectomy and Fusion
Procedure
Lead sponsor
LifeNet Health
Industry
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

BMAC & Allograft vs BMP-2

NCT02924571
View directory record Official record
Conditions
Spinal Fusion
Interventions
Bone Marrow Aspirate Concentrate (BMAC) + Allograft, Recombinant Human Bone Morphogenetic Protein-2 (BMP), Autograft
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 2, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

NCT02808585
View directory record Official record
Conditions
Heart Failure
Interventions
PB1046 Injection, Placebo Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 2, 2026, 10:04 PM EDT
Terminated Phase 2 Interventional Results available

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

NCT04985604
View directory record Official record
Conditions
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAF Mutation
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 2, 2026, 10:04 PM EDT
Withdrawn Phase 1 Interventional

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

NCT05700630
View directory record Official record
Conditions
HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection, Interleukin
Interventions
FT538, Vorinostat
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 2, 2026, 10:04 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

NCT07778836
View directory record Official record
Conditions
Friedreich Ataxia, Friedreich's Ataxia
Interventions
Nomlabofusp, Placebo
Drug
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Eatontown, New Jersey • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

Atacicept in Multiple Glomerular Diseases

NCT06983028
View directory record Official record
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 2, 2026, 10:04 PM EDT